secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q32 Bio Inc. (QTTB)
CIK:        0001661998
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001193125-26-205006
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q32 Bio reports Q1 2026 net loss of $7.6M; bempikibart trial on track for mid-2026 data
--------------------------------------------------------------------------------

- Cash $50.8M at Mar 31; plus $14.2M ATM proceeds post-Q and milestone payments fund into 1H 2028.
- Net loss $7.6M ($0.54 EPS) vs $11.0M ($0.90) in Q1 2025.
- Bempikibart Part B SIGNAL-AA 36-wk topline data readout on track for mid-2026; first OLE patient dosed.
- Completed $10.5M registered direct offering in Feb 2026 (1.7M shares/pre-funded warrants at $3.90).
- R&D expenses fell to $3.2M from $7.1M due to headcount reduction and ADX-097 sale.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661998/000119312526205006/0001193125-26-205006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661998/000119312526205006/qttb-20260505.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-205006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer